Direxion launches new nanotechnology ETF TYNE

0

On Tuesday, Direxion announced the launch of the Direxion Nanotechnology ETF (TYNE). TYNE invests in companies recognized as pioneers in nanotechnology, spanning the traditional consumer discretionary, healthcare, industrial, information technology and materials sectors.

“Investors continue to look for exposure to disruptive industries, but one important area that they may not fully appreciate is nanotechnology,” said nanotechnology David Mazza, Managing Director, Product Manager at Direxion. “Nanotech is used in a wide variety of companies today, from agriculture to biotechnology, defense to energy and semiconductors. With this innovation, materials can be made stronger, lighter, more durable and more reactive, which contributes to lowering costs and increasing productivity. “

TYNE seeks investment results before fees and expenses on the S&P Kensho Extended Nanotechnology Index. The S&P Kensho Extended Nanotechnology Index tracks the performance of US-listed companies that are involved in the creation and / or manipulation of matter at the molecular (or smaller) level by providing one or more of the following four types of products or services offer: manufacturing and manufacturing processes, measurement and simulation, materials and conveyor systems.

Investors seeking exposure to nanotech stocks and the nanotech sector can look to US-listed nanotech companies such as Moderna, Inc. (MRNA), Thermo Fisher Scientific (TMO), Nano Dimension Ltd. ADR (NNDM), BionTech SE (BNTX). , Beam Therapeutics Inc. (BEAM), and others about this nanotech ETF. You can find more Nanotech stocks in the table below.

away November 12, 2021, the 29 constituents had an average total market capitalization of $ 4 billion, Total market capitalizations of $ 98 million to $ 250 billion, and focused on the healthcare and information technology sectors. The top ten index positions are as follows:

Surname

ticker

GICS sub-branch

Market Capitalization ($ M)

Weight (%)

Arcturus Therapeutics Holdings Inc.

ARCT

biotechnology

1,183

11.74

Bruker BioSciences Corp.

BRKR

Scientific manufacturing

12,127

8.83

Beam Therapeutics Inc.

BEAM

biotechnology

5,890

8.66

Nano Dimension Ltd. ADR

NNDm

3d printing

1,508

6.32

Moderna, Inc.

MRNA

biotechnology

139,343

4.97

Intellia Therapeutics, Inc.

NTLA

biotechnology

9,772

4.73

BionTech SE

BNTX

biotechnology

66,386

3.64

Thermo Fisher Scientific

TMO

biotechnology

249,062

3.59

Alkermes plc

ALKS

biotechnology

4,887

3.56

Angiodynamics Inc

ANGO

Medical equipment

1,099

3.30

Source: Source: Bloomberg Finance, LP, S&P, as of 10/31/2021.

More news, information and strategies can be found in the Leveraged & Inverse Channel.


About Direxion:

Direxion provides traders with opportunities to execute short term, tactical trades and investors with strategic exposures and thematic strategies that focus on emerging trends. The company, founded in 1997, has approx. $ 25.1 billion in assets under management September 30, 2021.

Direxion shares risks –
Investing involves risks, including the possible loss of major nanotechnology-related businesses, can rely on a combination of patents, copyrights, trademarks and trade secrets to create and protect their property rights in their products and technologies, and can do so through the loss or impairment of these rights. In addition, nanotechnology companies may have limited product lines, markets, financial resources, or human resources. Nanotechnology companies can be smaller, less experienced companies that may be more volatile than the overall market. Small and micro-cap companies often have limited product lines, tighter markets for their goods and / or services, and more limited management and financial resources than larger, more established companies.

There is no guarantee that the investment strategy will be successful. The Fund’s other risks include but are not limited to index correlation / tracking risk, index strategy risk, natural disaster / epidemic and market disruption risk, and risks related to market capitalization and the sectors of the securities in which the Fund may invest. A more detailed description of these and other risks of the Fund can be found in the summary and in the full prospectus.

For more information, visit www.direxion.com.


Source link

Share.

Comments are closed.